Wugen Revenue and Competitors
Estimated Revenue & Valuation
- Wugen's estimated annual revenue is currently $18.6M per year.
- Wugen's estimated revenue per employee is $155,000
- Wugen's total funding is $172M.
Employee Data
- Wugen has 120 Employees.
- Wugen grew their employee count by -6% last year.
Wugen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | VP, Quality | Reveal Email/Phone |
4 | VP Clinical Operations | Reveal Email/Phone |
5 | VP, Finance and Business Operations | Reveal Email/Phone |
6 | Director Quality Assurance | Reveal Email/Phone |
7 | Director Information Technology | Reveal Email/Phone |
8 | Associate Director, Operational Excellence | Reveal Email/Phone |
9 | Sr. Director, Head Supply Chain & Procurement | Reveal Email/Phone |
10 | Chief Medical Officer | Reveal Email/Phone |
Wugen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $79.4M | 512 | 0% | N/A | N/A |
#2 | $1.1M | 7 | 0% | N/A | N/A |
#3 | $2.5M | 16 | 33% | N/A | N/A |
#4 | $5M | 32 | 14% | N/A | N/A |
#5 | $1.1M | 7 | 17% | N/A | N/A |
#6 | $6M | 39 | 3% | N/A | N/A |
#7 | $3.4M | 22 | -8% | N/A | N/A |
#8 | $0.3M | 4 | 0% | N/A | N/A |
#9 | $7.4M | 48 | 50% | N/A | N/A |
#10 | $5.7M | 37 | 0% | N/A | N/A |
What Is Wugen?
An "Off-the-Shelf" Fratricide Resistant CAR-T for the treatment of T-cell hematologic malignancies
keywords:N/A
$172M
Total Funding
120
Number of Employees
$18.6M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Wugen News
Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies...
Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) and CAR-T cell...
ST. LOUIS St. Louis-based clinical-stage biotechnology startup Wugen, which has raised more than $200 million in venture funding,...
San Diego-based Wugen, a biotechnology company which is developing treatments for solid tumors, recently annoucned a $172M, Series B funding round. The company--which says it licensed its technology from Washington University in St. Louis--said the Series B was co-led by Abingworth and Tybourne ...
Wugen, a Sant Louis MO- and San Diego CA-based clinical stage biotechnology company, raised $172M in Series B funding. The round was led by Abingworth and Tybourne Capital Management with participation from Fidelity Management & Research Company, Intermediate Capital Group (ICG), Sands Capital, ...
Other Companies in St Louis
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $17.4M | 120 | 22% | N/A |
#2 | $18.6M | 120 | -11% | $78M |
#3 | $3.5M | 122 | 9% | N/A |
#4 | $60.9M | 125 | 172% | N/A |
#5 | $34.8M | 129 | 17% | N/A |